HRPC(SH:600829)2025-10-20 09:05Financial Performance - The company's operating revenue for Q3 2025 was approximately CNY 2.70 billion, a slight increase of 0.15% compared to the same period last year[2]. - The total profit for the period was CNY 52.70 million, representing a decrease of 43.58% year-on-year[5]. - The net profit attributable to shareholders was CNY 39.30 million, down 44.51% compared to the previous year[5]. - Total operating revenue for the first three quarters of 2025 reached ¥7,845,928,889.11, an increase from ¥7,678,084,114.44 in the same period of 2024, representing a growth of approximately 2.2%[20]. - Net profit for the first three quarters of 2025 was ¥111,876,512.82, down from ¥206,004,237.80 in 2024, indicating a decline of approximately 45.6%[22]. - The company reported a total profit of ¥150,465,764.18 for the first three quarters of 2025, down from ¥270,306,131.53 in 2024, a decline of approximately 44.3%[21]. - Basic earnings per share for the first three quarters of 2025 were ¥0.1929, compared to ¥0.3552 in 2024, reflecting a decrease of about 45.8%[22]. Cash Flow - The net cash flow from operating activities was negative CNY 313.94 million for the year-to-date, indicating a significant cash outflow[5]. - The net cash flow from operating activities for the first three quarters of 2025 was -¥313,939,721.76, compared to -¥243,296,367.64 in 2024, worsening by about 29%[24]. - Cash and cash equivalents at the end of September 2025 stood at ¥597,718,580.27, down from ¥733,996,899.23 at the end of September 2024, a decrease of approximately 18.5%[26]. - Total cash outflow from operating activities amounted to $5,527,797.96, down from $11,024,895.25[35]. - The net cash flow from investment activities was -$120,000.00, reflecting no cash inflow from investments[35]. Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 7.02 billion, a decrease of 2.01% from the previous year[3]. - As of September 30, 2025, total current assets amount to ¥6,542,609,377.72, a decrease from ¥6,686,906,764.87 at the end of 2024[16]. - Total liabilities decreased to ¥4,029,008,813.63 from ¥4,285,037,426.87, a reduction of approximately 5.97%[18]. - Total assets as of September 30, 2025, were CNY 1,657,253,864.43, slightly down from CNY 1,659,843,414.48 as of December 31, 2024[28]. - Total liabilities as of September 30, 2025, were CNY 57,009,092.11, increasing to CNY 58,188,357.11 by December 31, 2024[29]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 27,745[11]. - The largest shareholder, Harbin Pharmaceutical Group Co., Ltd., holds 433,894,354 shares, accounting for 74.82% of total shares[11]. - The company has no reported changes in the top 10 shareholders or their shareholding status due to margin trading[13]. Operational Insights - The retail segment saw a revenue increase of CNY 26.20 million, growing 21.14% year-on-year, driven by the expansion of DTP business sales[4]. - The company reported a net profit margin decline due to tightening gross margins in the wholesale segment influenced by procurement policies[5]. - The company plans to continue enhancing its professional pharmaceutical service capabilities to drive future growth in the retail segment[4]. - The company has not disclosed any new product developments or market expansion strategies in the provided data[14]. - There are no significant reminders or additional important information regarding the company's operational status during the reporting period[14]. Cost and Expenses - Total operating costs increased to ¥7,640,840,977.23 in 2025 from ¥7,399,719,919.24 in 2024, reflecting a rise of about 3.3%[21]. - The company incurred a financial expense of ¥21,608,311.44 in 2025, up from ¥16,717,988.17 in 2024, marking an increase of approximately 29%[21]. - The company reported a significant increase in management expenses, rising to CNY 2,311,730.49 in 2025 from CNY 1,986,736.86 in 2024, an increase of approximately 16.4%[31]. Accounting and Reporting - The company did not adopt new accounting standards starting from 2025[36]. - The financial report was announced by the board of directors on October 20, 2025[37].